Thermo Fisher Launches CDMO and CRO Services at CPHI Milan 2024
Thermo Fisher Scientific launched its Accelerator Drug Development in 2024 after expanding R&D, production, and testing locations in Cincinnati, Ohio, and Bend, Oregon
On October 7, 2024, Thermo Fisher Scientific shared exciting news about the launch of the Accelerator Drug Development. This initiative offers comprehensive contract development and manufacturing organization services, along with contract research organization solutions for drug development. The announcement was made in conjunction with CPHI Milan 2024, taking place in Milan, Italy from October 8 to 10, 2024. The new services offering is included in the company's presentation at the conference, as stated in a company press release.
The company states that Accelerator Drug Development will influence the pharmaceutical value chain for both biotech and large pharmaceutical firms by offering customizable services in manufacturing, clinical research, and clinical supply chain for small molecules, biologics, and cell and gene therapies. The services aim to help customers throughout all phases of the drug development process.
“Thermo Fisher is changing how drugs are developed and made to help customers advance important programs quickly, with high quality and efficiency,” said Michael Shafer, executive vice president and president, biopharma services, Thermo Fisher Scientific, in the press release. “We link the stages from finding to providing—covering initial testing and analysis, designing clinical research, conducting trials, managing the clinical supply chain, manufacturing, and scaling up for commercial use. Our goal is to make transitions smooth, reduce risks, and speed up innovation at each step.”
The introduction of Accelerator Drug Development follows a productive summer for Thermo Fisher in 2024. In June, they opened a new building at their good manufacturing practice (GMP) facility in Middleton, Wisconsin, and in July, they announced the successful acquisition of Olink Holding, a company from Sweden that specializes in next-generation proteomics solutions. The company has grown its locations in Cincinnati, Ohio, and Bend, Ore., to improve research and development, manufacturing, and testing for oral solid dose drug formulations.
Source: Thermo Fisher Scientific
